+34 679 490 537info@nanbiosis.com

Posts Taged type-2-diabetes

Researchers of NANBIOSIS U3 find activators of a possible therapeutic target for the treatment of patients with diabetes and insulin resistance

Researchers of  NANBIOSIS U3: Synthesis of Peptides Unit participate in the identification of activators of of the mitochondrial protein Mitofusin 2, a possible therapeutic target for the treatment of patients with type 2 diabetes in collaboration with CIBER of Diabetes and Associated Metabolic Diseases (CIBERDEM) and the CIBER of Bioengineering, Biomaterials and Nanomedicine (CIBER-BBN).

Those researchers are led by Fernando Albericio (Scientific Director of Unit 3 of NANBIOSIS) at the University of Barcelona and Antonio Zorzano en el IRB Barcelona  have identified activators of the mitochondrial protein Mitofusin 2 for the treatment of type 2 diabetes. This protein is expressed at abnormally low levels in the tissues of patients with diabetes. “Thanks to the studies of phenotypic screening and validation studies in human cells, it has been possible to demonstrate the role of the protein Mitofusin 2 in the development of many of the alterations associated with diabetes”, explain those responsible for the work.

These studies have been possible thanks to the work of biologists and chemists from different CIBER areas and with experience in synthetic chemistry, molecular screening and functional analysis.

Article of reference:

Identification of New Activators of Mitochondrial Fusion Reveals a Link between Mitochondrial Morphology and Pyrimidine Metabolism. Miret-Casals L, Sebastián D, Brea J, Rico-Leo EM, Palacín M, Fernández-Salguero PM, Loza MI, Albericio F, Zorzano A. Cell Chem Biol. 2017 Dec 23. pii: S2451-9456(17)30428-2. doi: 10.1016/j.chembiol.2017.12.001.

Read More

Midyear meeting in Vitoria of European project DRIVE

CIBER-BBN participates in the project through NanoBioCel group, led by professor José Luis Pedraz Muñoz, Scientific Director of Unit 10 of NANBIOSIS, working on the optimization of formulations to be included in a bioartificial organ.

José Luis Pedraz Munoz and Jesus Izco coordinator of NANBIOSIS have participated in the meeting held in Vitoria on 3 and 4 of October.

The DRIVE objective is to develop new biomaterials and devices surgical transplantation and improve islet survival producing pancreatic insulin for the treatment of diabetes. Diabetes Mellitus is a chronic disease characterized by high blood glucose levels and affects 422 million people in the world, according to 2014 World Health Organization (WHO).

DRIVE is a four-year European project funded by the Horizon 2020 program for research and innovation of the Union European and endowed with 8.9 million euros. It is being conducted by 14 European partners and coordinated by the Royal College of Surgeons Ireland (Royal College of Surgeons in Ireland). Seeks to develop a bioartificial pancreas that is inserted into the body through minimally invasive techniques. To do this, they are being carried out preclinical studies to integrate this system in the human body and assess its effectiveness in people. The system will contain islets Pancreatic to restore the natural control of blood sugar and eliminate the need for multiple daily injections of insulin, thus improving the quality of life of patients.

Midyear meeting in Vitoria of European project DRIVE
Read More

Nanbiosis in the 2ª General Assambly of DRIVE project, Venice (16th-17th 2016)

Jesus Izco, Coordinator of NANBIOSIS and José Luis Pedraz, Scientific Director of Unit 10-Drug Formulation  of NANBIOSIS and NanoBioCel Group of CIBER-BBN, participated in the 2ª General Assambly of  DRIVE project, held in Venice, May 16th-17th 2016.

The second General Assembly of European project DRIVE “DIABETES-REVERSING-IMPLANTS FOR ENHANCED VIABILITY AND LONG TERM EFFICACY”, took place last 16 and 17 of May in San Servolo Island, Venice. Jesus Ciriza, from NanoBioCel  group, presented the work scheduled for this first year and the results obtained.

The DRIVE, a 4-year project to be carried out by 14 European partners, among which is CIBER-BBN, develops biomaterials and new surgical devices to improve transplantation and survival of insulin-producing pancreatic islet for the treatment of diabetes.

CIBER-BBN participates in the project thought Unit 10 of NANBIOSIS with the role of:

-Development of hydrogel formulations for β-Gel

-Developing unlimited future sources of insulin-producing β-cells

-Testing β-cell function in β-Gel using 3D in vitro tissue model.

Jesus Izco, Coordinator of NANBIOSIS and José Luis Pedraz, Scientific Director of Unit 10-Drug Formulation of NANBIOSIS and NanoBioCel Group of CIBER-BBN, participated in the 2ª General Assambly of DRIVE project, held in Venice, May 16th-17th 2016.
Read More
Nanbiosis